SI
KROS icon

Sofinnova Investments’s Keros Therapeutics KROS Stock Holding History

Sofinnova Investments’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-95,375
Closed -$1.51M – 78
2024
Q4 		$1.51M Buy
+95,375
New +$4.96M 0.11% 50
2023
Q2 		– Sell
-77,100
Closed -$3.29M – 57
2023
Q1 		$3.29M Buy
+77,100
New +$3.89M 0.21% 45

Other funds holding KROS

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Sofinnova Investments's KROS Position: Q1 2025 in Review

Sofinnova Investments sold out of Keros Therapeutics (KROS) in Q1 2025, closing a stake of 95,375 shares — an estimated $1.51M sold.

Sofinnova Investments first reported a position in KROS in Q1 2023 and held it in 2 quarters. The position peaked at $3.29M in Q1 2023. 156 funds tracked by Wall St. Rank hold KROS as of Q1 2025.

  • Sofinnova Investments reported no remaining Keros Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Sofinnova Investments sold 95,375 Keros Therapeutics shares in Q1 2025, an estimated $1.51M.
  • Sofinnova Investments first reported a position in Keros Therapeutics in Q1 2023 and held it in 2 quarters.
  • Sofinnova Investments's Keros Therapeutics position peaked at $3.29M in Q1 2023.
  • 156 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2025.

Based on Sofinnova Investments's 13F filing for Q1 2025, filed 15 May 2025.